Podcast
CAPITOL WEEKLY PODCAST: We’re joined by Mariel Garza, co-founder and executive editor of the Golden State Report. Garza was a longtime reporter and editor for mainstream California news organizations, including the Sacramento Bee and the Los Angeles Times, until she abruptly resigned from the Times’ editorial board in October 2024 after owner Dr. Patrick Soon-Shiong blocked publication of an endorsement of Kamala Harris for president.
News
Reason exists for some optimism among California’s clinical researchers – a $12 billion ballot initiative actually on the fall ballot. It is Proposition 38, which would provide $8.4 billion for immunology research involving a wide range of afflictions, including cancer, heart disease and Alzheimer’s disease.
Micheli Minute
Lobbyist, author and McGeorge law professor Chris Micheli offers a quick look at what’s coming up this week under the Capitol Dome.
Opinion
California’s education leaders are currently determining what instructional materials will sit on teachers’ desks for years to come.
Podcast
CAPITOL WEEKLY PODCAST: A poll from Median Strategies roiled the Los Angeles mayoral race earlier this month, showing Mayor Karen Bass with an 11 point lead over challenger Nithya Raman. The results were cited by several media outlets, and were touted by the Bass campaign before the poll was exposed as fake. Political data expert Paul Mitchell joined us to talk about how junk polls, paid influencers and strategic gaming of prediction markets can distort perceptions about a campaign.
News
As his time as governor comes to an end, Gov. Gavin Newsom is facing a life-or-death decision: whether to commute the sentences of the 547 men and 18 women in state prison who have been condemned to death. There is good reason to believe Newsom will take that step, and there is reason to believe he won’t. Neither he nor his aides are telegraphing his plan.
Micheli Files
In reviewing legislation during the last month of the 2026 California Legislative Session, I have come across a number of examples of excellent bill drafting and wanted to draw attention to them to serve as guides in the upcoming 2027 Legislative Session.
Opinion
When a specialist prescribes an FDA-approved treatment for the rare disease it was built for, let the patient have it.